Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS-mutant cancer.

EMBO molecular medicine - 7 Sept 2021

Yang Zhang, Liang Shun-Qing, Saliakoura Maria, Yang Haitang, Vassella Eric, Konstantinidou Georgia, Tschan Mario, Hegedüs Balazs, Zhao Liang, Gao Yanyun, Xu Duo, Deng Haibin, Marti Thomas M, Kocher Gregor J, Wang Wenxiang, Schmid Ralph A, Peng Ren-Wang

Abstract excerpt

KRAS oncoprotein is commonly mutated in human cancer, but effective therapies specifically targeting KRAS-driven tumors remain elusive. Here, we show that combined treatment with fibroblast growth factor receptor 1 (FGFR1) and polo-like kinase 1 (PLK1) inhibitors evoke synergistic cytotoxicity in KRAS-mutant tumor models in vitro and in vivo. Pharmacological and genetic suppression of FGFR1 and PLK1 synergizes to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle Proteins
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Polo-Like Kinase 1

Share to Protein Serine-Threonine Kinases

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to Receptor, Fibroblast Growth Factor, Type 1

Source

Open in PubMed Open full text

Identifiers

PMID: 34369083
DOI: 10.15252/emmm.202013193
PMCID: PMC8422071

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS-mutant cancer.PMID 34369083Read ↗

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK.Semantic proximity Read ↗

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS.Semantic proximity Read ↗

A combinatorial strategy for treating KRAS-mutant lung cancer.Semantic proximity Read ↗

PLCγ1 suppression promotes the adaptation of KRAS-mutant lung adenocarcinomas to hypoxia.Semantic proximity Read ↗

Inhibition of Polo-like kinase 1 (PLK1) triggers cell apoptosis via ROS-caused mitochondrial dysfunction in colorectal carcinomaSemantic proximity Read ↗

Synthetic Lethality of a Novel Small Molecule Against Mutant KRAS-Expressing Cancer Cells Involves AKT-Dependent ROS ProductionSemantic proximity Read ↗

A novel MTORC2-AKT-ROS axis triggers mitofission and mitophagy-associated execution of colorectal cancer cells upon drug-induced activation of mutant KRAS.Semantic proximity Read ↗

Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancerSemantic proximity Read ↗

Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer.Semantic proximity Read ↗

Rational application of targeted therapeutics in mucinous colon/appendix cancers with positive predictive factors.Semantic proximity Read ↗

Romidepsin inhibits NRF2 and enhances the efficacy of adagrasib by inducing autophagic cell death in KRAS-mutant tumor cells.Semantic proximity Read ↗

Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.